Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

RAPT Therapeutics weakness creates a long-term opportunity - UBS

Published 15/03/2023, 15:10
© Reuters.
RAPT
-

By Sam Boughedda

RAPT Therapeutics (NASDAQ:RAPT) shares fell more than 25% on Tuesday, but UBS analysts believe the stock's weakness creates a long-term opportunity.

On Tuesday, RAPT reported fourth-quarter financials, and UBS spoke with the company's management after the release.

"New from today's release is topline data from the Ph2B of RPT193 in atopic dermatitis is now guided for mid-24 vs 2H23 previously, with the company citing slower than expected enrollment of patients due to the lack of an expected seasonal uptick. We see this as a meaningful update given investor focus on what had been the upcoming catalyst for '193 this year," wrote the analysts, who maintained a Buy rating and $61 price target on the stock.

The analysts said the firm noted the share price decrease following the results, which they think is "largely due to shifted timing of atopic derm catalyst," but there is no change in their view of the "program's fundamentals and potential opportunity of '193 if successful in atopic derm."

"We continue to see a large opportunity for a safe oral in atopic derm and see '193 as a highly promising agent based on what we've seen so far from Ph1b data (though early)," they added. "We see atopic derm data as a major catalyst for 2024, with significant upside potential in 2H24 if successful. Despite the delay, we have conviction in shares longer-term, with a market cap of ~$920M vs we estimate over $2B potential peak '193 sales if successful. The company ended the year with cash of ~$249M, which it expects to provide runway beyond the 2024 data read into mid-2025."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.